A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects
with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after
administration of Symbicort pMDI 160/4.5 μg.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate